Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL442426 | 0.72 | CA12 (0.44) | HRH4CES1 | |
| SCHEMBL16456504 | 0.72 | KDM4E (0.41) | KDM4EPOLB | |
| SCHEMBL593971 | 0.69 | KDM4E (0.58) | KIF11SMN1; SMN2KDM4EHSD17B10MEN1 | |
| SCHEMBL9740425 | 0.68 | CYP1A2 (0.39) | SMN1; SMN2KDM4EHSD17B10MEN1KMT2A | |
| SCHEMBL4455876 | 0.68 | AHR (0.48) | MEN1KMT2APOLBLMNAGAA | |
| SCHEMBL4465569 | 0.68 | CYP2A6 (0.39) | KIF11ALDH1A1POLBGAAMAPT | |
| SCHEMBL9739424 | 0.68 | AXL (0.50) | KIF11SMN1; SMN2KDM4EHSD17B10MEN1 | |
| SCHEMBL4477406 | 0.67 | NOS1 (0.53) | SMN1; SMN2KDM4EHSD17B10MEN1KMT2A | |
| SCHEMBL31083618 | 0.66 | KIF11 (0.74) | KIF11SMN1; SMN2KDM4EHSD17B10MEN1 | |
| SCHEMBL3814961 | 0.65 | KIF11 (0.40) | KIF11SMN1; SMN2KDM4EHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620391-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-7790710-B2 | Imidazopyridine derivatives useful as iNOS inhibitors | NYCOMED GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| EP-1866306-B1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2009-06-17 | — | — | EP | disclosed |
| US-20090131399-A1 | Imidazopyridine Derivatives Useful as iNOS Inhibitors | NYCOMED GMBH (DE) | 2009-05-21 | — | — | US | disclosed |
| EP-1673371-B1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | NYCOMED GMBH (DE) | 2008-08-06 | — | — | EP | disclosed |
| US-20080125460-A1 | Imidazopyridine-Derivatives As Inducible No-Synthase Inhibitors | ALTANA PHARMA AG (DE) | 2008-05-29 | — | — | US | disclosed |
| EP-1866306-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | Nycomed GmbH (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103255-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2006-10-05 | — | — | WO | disclosed |
| EP-1673371-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA Pharma AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030769-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125460-A1 | Imidazopyridine-Derivatives As Inducible No-Synthase Inhibitors | PTGS1, PTGIS, NOS1 | KIF11 4883/4885SMN1; SMN2 4465/4885KDM4E 3033/4885 |
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NOS2, NOS1, ARG1 | KIF11 4857/4885SMN1; SMN2 3333/4885KDM4E 2894/4885 |
| US-20090131399-A1 | Imidazopyridine Derivatives Useful as iNOS Inhibitors | NOS2, NOS1, ARG1 | KIF11 4857/4885SMN1; SMN2 3333/4885KDM4E 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.